Please login to the form below

Not currently logged in
Email:
Password:

FDA declines approval for Eisai's Aricept

Eisai has received a complete response letter from the US Food and Drug Administration declining approval for the transdermal patch formulation of Eisai's Alzheimer's treatment Aricept

Eisai has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) declining approval for the transdermal patch formulation of Eisai's Alzheimer's treatment Aricept (donepezil hydrochloride).

The FDA has requested more information regarding the formulation and usage of the form of treatment.

Eisai has said it will collaborate with its US partner, Teikoku Pharma, and work with FDA to assess the complete response letter and determine next steps.

Teikoku developed the transdermal patch formulation of Aricept based on licence agreements with Eisai.

In June 2010, Teikoku submitted a new drug application to the FDA seeking approval to use the specific formulation of Aricept in the treatment of mild, moderate and severe stages of Alzheimer's disease.

26th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics